Cutaneous Tuberculosis: a Review of the Current Literature
- 4 Downloads
Purpose of review
This review summarizes the literature currently available for cutaneous tuberculosis (CTB), as well as providing data for clinical utility.
Available studies in CTB are scarce; however, they provide important information about efficacy and outcome in clinical practice.
We can detect differences in the clinical aspect and disease evolution; this is due to the individual immunity, environmental factors, and the type of inoculum. Treatment options for CTB are currently limited to the conventional oral therapy and the occasional surgical intervention in cases where needed. The development of multidrug-resistant strains and extremely resistant to drugs has also threatened treatment effectiveness. The aim of the article is to review the current status of CTB, in addition to a better knowledge of the molecular and cellular mechanisms regulating host-agent interaction.
KeywordsMycobacterium tuberculosis Tuberculosis Cutaneous tuberculosis
Compliance with Ethical Standards
Conflict of Interest
Andrés Tirado-Sánchez and Alexandro Bonifaz declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Nadjane Batista Lacerda S, Cristina de Abreu Temoteo R, Maria Ribeiro Monteiro de Figueiredo T, Darliane Tavares de Luna F, Alves Nunes de Sousa M, Carlos de Abreu L, et al. Individual and social vulnerabilities upon acquiring tuberculosis: a literature systematic review. Int Arch Med. 2014;7:35.CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva: World Health Organization; 2014.Google Scholar
- 5.• Melsew YA, Doan TN, Gambhir M, Cheng AC, McBryde E, Trauer JM. Risk factors for infectiousness of patients with tuberculosis: a systematic review and meta-analysis. Epidemiol Infect. 2018;1-9. This paper shows a summary of the most commonly seen risk factors for tuberculosis.Google Scholar
- 9.•• Bainomugisa A, Lavu E, Hiashiri S, Majumdar S, Honjepari A, Moke R, et al. Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades. Microb Genom. 2018; https://doi.org/10.1099/mgen.0.000147. This paper gives important clues for the mechanisms of drug-resistance in tuberculosis.
- 17.Marín D, Marín N, Del Corral H, López L, Ramirez-Agudelo ME, Rojas CA, et al. PPD-induced monocyte mitochondrial damage is associated with a protective effect to develop tuberculosis in BCG vaccinated individuals: a cohort study. PLoS One. 2017;12(2):e0171930.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.•• Hill MK, Sanders CV. Cutaneous tuberculosis. Microbiol Spectr. 2017;5(1) https://doi.org/10.1128/microbiolspec.TNMI7-0010-2016. This paper gives important strategies for treating cutaneous tuberculosis.
- 25.Boortalary T, Misra K, McNish S, Jones D, Shanmugam VK. Prevalence of positive QuantiFERON gold in-tube testing in Hidradenitis suppurativa. J Dermatolog Treat 2018;1–16.Google Scholar
- 26.Matono T, Nishijima T, Teruya K, Morino E, Takasaki J, Gatanaga H, et al. Substantially higher and earlier occurrence of anti-tuberculosis drug-related adverse reactions in HIV coinfected tuberculosis patients: a matched-cohort study. AIDS Patient Care STDs. 2017;31(11):455–62.CrossRefPubMedGoogle Scholar